HUE045311T2 - Polianionos, többértékû makromolekulák a szaporodás és a fehérjeszintézis intracelluláris megcélzására - Google Patents

Polianionos, többértékû makromolekulák a szaporodás és a fehérjeszintézis intracelluláris megcélzására

Info

Publication number
HUE045311T2
HUE045311T2 HUE11701951A HUE11701951A HUE045311T2 HU E045311 T2 HUE045311 T2 HU E045311T2 HU E11701951 A HUE11701951 A HU E11701951A HU E11701951 A HUE11701951 A HU E11701951A HU E045311 T2 HUE045311 T2 HU E045311T2
Authority
HU
Hungary
Prior art keywords
proliferation
protein synthesis
intracellular targeting
polyanionic
macromolecules
Prior art date
Application number
HUE11701951A
Other languages
English (en)
Inventor
Kai Licha
Michael Schirner
Pia Welker
Rainer Haag
Marie Weinhart
Florian Paulus
Original Assignee
Nanopet Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanopet Pharma Gmbh filed Critical Nanopet Pharma Gmbh
Publication of HUE045311T2 publication Critical patent/HUE045311T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • A61K49/124Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/06Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE11701951A 2010-02-03 2011-01-31 Polianionos, többértékû makromolekulák a szaporodás és a fehérjeszintézis intracelluláris megcélzására HUE045311T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10001104 2010-02-03
EP10001655 2010-02-18
EP10002121 2010-03-02

Publications (1)

Publication Number Publication Date
HUE045311T2 true HUE045311T2 (hu) 2019-12-30

Family

ID=43981117

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11701951A HUE045311T2 (hu) 2010-02-03 2011-01-31 Polianionos, többértékû makromolekulák a szaporodás és a fehérjeszintézis intracelluláris megcélzására

Country Status (13)

Country Link
US (1) US8877171B2 (hu)
EP (1) EP2531221B1 (hu)
JP (2) JP5866301B2 (hu)
CN (1) CN102781478A (hu)
AU (1) AU2011212742B2 (hu)
BR (1) BR112012019520A2 (hu)
CA (1) CA2788736C (hu)
DK (1) DK2531221T3 (hu)
ES (1) ES2730744T3 (hu)
HU (1) HUE045311T2 (hu)
NZ (1) NZ601550A (hu)
PL (1) PL2531221T3 (hu)
WO (1) WO2011095311A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014051109A1 (ja) * 2012-09-28 2016-08-25 協和発酵キリン株式会社 抗ヒトbmp9抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
WO2014114183A1 (zh) * 2013-01-23 2014-07-31 北京市丰硕维康技术开发有限责任公司 一种治疗肿瘤细胞增生性疾病的铂(ii)类化合物
EP2923695A1 (en) 2014-03-25 2015-09-30 DendroPharm GmbH Hyperbranched polyglycerol sulfates with hydrophobic cores
WO2015170573A1 (ja) * 2014-05-08 2015-11-12 公立大学法人大阪府立大学 リンパ節イメージング剤
ES2856324T3 (es) 2014-05-13 2021-09-27 Dendropharm Gmbh Formulaciones para el tratamiento del hipertiroidismo
EA036983B1 (ru) * 2014-05-21 2021-01-22 АйСиДи-ТЕРАПЬЮТИКС ГМБХ Терапевтические конъюгаты с сульфатированными дендримерами для внутриклеточного нацеливания
EP3048130A1 (en) * 2015-01-20 2016-07-27 Freie Universität Berlin Anionic linear polyglycerol derivatives, a method for manufacturing and applications
US10525141B2 (en) 2015-04-15 2020-01-07 Freie Universität Berlin Polyglycerol derivative and a method for manufacturing the same
DE102015121366A1 (de) 2015-12-08 2017-06-08 Dendropharm Gmbh Analgetische Zusammensetzungen mit Nanocarriern und ihre Verwendung
EP3484527A1 (en) 2016-07-13 2019-05-22 Freie Universität Berlin Polyglycerol derivative for use in diagnosing a disease at an early stage
EP4134073A1 (en) 2021-08-11 2023-02-15 HM HerbaMedica GmbH Pharmaceutical compositions comprising dendritic nanocarriers and cannabis active agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
AU678469B2 (en) * 1993-05-03 1997-05-29 Genentech Inc. Inhibition of leukocyte adhesion
US5952499A (en) 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
AU4497096A (en) 1995-01-30 1996-08-21 Daiichi Pure Chemicals Co., Ltd. Diagnostic marker
JPH11140038A (ja) * 1997-11-04 1999-05-25 Kanebo Ltd カルボン酸誘導体
JPH11246503A (ja) * 1998-03-04 1999-09-14 Sumitomo Pharmaceut Co Ltd シクロヘキサン誘導体
DE10056136A1 (de) * 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
EP1450790A4 (en) 2001-10-03 2005-10-26 Miravant Pharm Inc PHOTOSENSIBILIZING CARBAMATE DERIVATIVES
CA2462261A1 (en) 2001-10-03 2003-04-10 Miravant Pharmaceuticals, Inc. Chlorin photosensitizing agents for use in photodynamic therapy
DE102006036326A1 (de) * 2006-08-03 2008-02-07 Charité - Universitätsmedizin Berlin Dendritische Polyglycerolsulfate und -sulfonate und deren Verwendung bei entzündlichen Erkrankungen
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
WO2009142893A2 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions for the delivery of bioactive compounds

Also Published As

Publication number Publication date
BR112012019520A2 (pt) 2018-03-13
AU2011212742B2 (en) 2014-09-04
US8877171B2 (en) 2014-11-04
US20130095035A1 (en) 2013-04-18
JP2013518841A (ja) 2013-05-23
JP2016026191A (ja) 2016-02-12
WO2011095311A1 (en) 2011-08-11
PL2531221T3 (pl) 2020-05-18
JP5866301B2 (ja) 2016-02-17
CA2788736C (en) 2020-03-31
EP2531221A1 (en) 2012-12-12
ES2730744T3 (es) 2019-11-12
NZ601550A (en) 2014-03-28
DK2531221T3 (da) 2019-06-17
AU2011212742A1 (en) 2012-08-30
CA2788736A1 (en) 2011-08-11
EP2531221B1 (en) 2019-03-13
CN102781478A (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
HUE045311T2 (hu) Polianionos, többértékû makromolekulák a szaporodás és a fehérjeszintézis intracelluláris megcélzására
HK1213488A1 (zh) 共軛的吡咯並苯並二氮雜卓衍生物的合成與中間體
IL230439B (en) Genes and proteins for the synthesis of alkanoyl-coenzyme - a
SG184289A1 (en) Novel peptides and methods for their preparation and use
HK1173440A1 (en) N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors n-(-7-)- pde10a
ZA201209145B (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
EP2521553A4 (en) METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS
EP2627349A4 (en) GENES OF OBESITY, THEIR PROTEINS AND USES THEREOF
GB2477264B (en) Eyeglasses and means for their adjustment
PT2655375E (pt) Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
ZA201302537B (en) Stable and soluble antibodies
AP3222A (en) Germination-stimulant carbamate derivatives and process for preparation thereof
IL231444A (en) Aniline derivatives, their preparation and their medical application
SG10201604467PA (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
WO2011126882A9 (en) Therapeutic peptides and their derivatives and therapeutic uses thereof
IL225771A0 (en) Indole history and process for their preparation
EP2739279A4 (en) NEW ANILINE DERIVATIVES AND ITS USE
IL233238A (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
EP2575897A4 (en) CROSSLINKING OF PROTEINS AND OTHER ENTITIES THROUGH ALPHA-HALO-ACETOPHENONES CONJUGATES, BENZYL HALIDES, QUINONES
EP2671573A4 (en) PLASTER AND PAVER MAKING
EP2671572A4 (en) TRANSDERMAL STAMP AND PREPARATION OF TRANSDERMAL STAMP
AP2013006816A0 (en) Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation
IL233083A0 (en) Preparations, synthesis and methods of use in the history of phenylcycloalkylmethylamine
IL221279A0 (en) Polyanionic multivalent macromolecules for intracellular targeting of proliferation and porotein synthesis
IL220859A0 (en) Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application